Log In
Print
BCIQ
Print
Print this Print this
 

galeterone (TOK-001)

  Manage Alerts
Collapse Summary General Information
Company Tokai Pharmaceuticals Inc.
DescriptionSelective androgen receptor modulator (SARM) and cytochrome P450 17 alpha-hydroxylase/C17,20 lyase (CYP17) inhibitor
Molecular Target Androgen receptor ; Cytochrome P450 17 alpha-hydroxylase/C17, 20 lyase (CYP17) (CYP17A)
Mechanism of ActionAndrogen receptor antagonist; Cytochrome P450 17alpha-hydroxylase/C17,20 lyase (CYP17) inhibitor
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentPhase II
Standard IndicationProstate cancer
Indication DetailsTreat castration-resistant prostate cancer (CRPC)
Regulatory Designation

U.S. - Fast Track (Treat castration-resistant prostate cancer (CRPC))

Partner


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today